Supplementary Materials

Supplementary Material for:

AZD3759, a BBB-penetrating EGFR inhibitor for the treatment of EGFR mutant NSCLC with CNS metastases

Zhenfan Yang, Qiuli Guo, Yingchun Wang, Kan Chen, Lin Zhang, Ziqiang Cheng, Yanping Xu, Xiaolu Yin, Yu Bai, Sarit Rabbie, Dong-Wan Kim, Myung-Ju Ahn, James Chih-Hsin Yang, Xiaolin Zhang*

*Corresponding author. Email: xiaolin.zhang{at}astrazeneca.com

Published 7 December 2016, Sci. Transl. Med. 8, 368ra172 (2016)
DOI: 10.1126/scitranslmed.aag0976

This PDF file includes:

  • Fig. S1. EGFR protein expression in lung cancer cell lines.
  • Fig. S2. Tumor growth curves of individual animals in the PC-9 LM model.
  • Fig. S3. Comparison of tumor areas on the leptomeninges in the PC-9 LM model.
  • Fig. S4. Tumor growth curves of individual animals in the PC-9 BM model.
  • Fig. S5. Comparison of tumor areas in the brain in the PC-9 BM model.
  • Fig. S6. Tumor growth curves of individual animals in the PC-9 BM prevention model.
  • Fig. S7. Tumor growth curves of individual animals in the H3255 SC model.
  • Fig. S8. Tumor growth curves of individual animals in the PC-9 SC model.
  • Fig. S9. Tumor growth curves of individual animals in the A549 SC model.
  • Fig. S10. Characterization of the PC-9 BM model.
  • Table S1. In vitro activity of AZD3759 in lung cancer cell lines.
  • Table S2. Estimation of human equivalent dose of erlotinib in nude mice.
  • Table S3. Tumor formation on the leptomeninges in the PC-9 LM model.
  • Table S4. Tumor formation in the brain in the PC-9 BM model.
  • Table S5. Tumor formation in the brain in the PC-9 BM prevention model.

[Download PDF]